Literature DB >> 15986378

Intrahepatic gene expression profiles and alpha-smooth muscle actin patterns in hepatitis C virus induced fibrosis.

Daryl T-Y Lau1, Bruce A Luxon, Shu-Yuan Xiao, Michael R Beard, Stanley M Lemon.   

Abstract

To gain insight into pathogenic mechanisms underlying fibrosis in hepatitis C virus (HCV)-mediated liver injury, we compared intrahepatic gene expression profiles in HCV-infected patients at different stages of fibrosis and alpha-smooth muscle actin (alpha-SMA) staining patterns. We studied 21 liver biopsy specimens: 5 had no fibrosis (Ludwig-Batts stage 0); 10 had early portal or periportal fibrosis (stages 1 and 2); and 6, advanced fibrosis (stages 3 and 4). None of the patients had hepatocellular carcinoma. Transcriptional profiles were determined by high-density oligonucleotide microarrays. ANOVA identified 157 genes for which transcript abundance was associated with fibrosis stage. These defined three distinct hierarchical clusters of patients. Patients with predominantly stage 0 fibrosis had increased abundance of mRNAs linked to glycolipid metabolism. PDGF, a potent stellate cell mitogen, was also increased. Transcripts with increased abundance in stages 1 and 2 fibrosis were associated with oxidative stress, apoptosis, inflammation, proliferation, and matrix degradation, whereas transcripts increased in stages 3 and 4 were associated with fibrogenesis and cellular proliferation. Cells staining for alpha-SMA were detectable at all stages but infrequent in advanced fibrosis without active inflammation. A high frequency of such cells was associated with mRNAs linked to glycolipid metabolism. In conclusion, the presence of alpha-SMA-positive HSCs and expression of PDGF in stage 0 fibrosis suggests that stellate cells are activated early in HCV-mediated injury, possibly in response to oxidative stress resulting from inflammation and lipid metabolism. Increased abundance of transcripts linked to cellular proliferation in advanced fibrosis is consistent with a predisposition to cancer. Supplementary material for this article can be found on the HEPATOLOGY website (http://www.interscience.wiley.com/jpages/0270-9139/suppmat/index/html).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15986378     DOI: 10.1002/hep.20767

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  26 in total

1.  Gene expression profiles during activation of cultured rat hepatic stellate cells by tumoral hepatocytes and fetal bovine serum.

Authors:  Yunhong Xia; Rongxin Chen; Zhenji Song; Shenglong Ye; Ruixia Sun; Qiong Xue; Zhe Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2010-02       Impact factor: 4.553

2.  Gene profiling of early and advanced liver disease in chronic hepatitis C patients.

Authors:  Saira Sarfraz Khalid; Saeed Hamid; Anwar A Siddiqui; Asaf Qureshi; Nilofer Qureshi
Journal:  Hepatol Int       Date:  2011-01-22       Impact factor: 6.047

3.  Role of simple biomarkers in predicting fibrosis progression in HCV infection.

Authors:  Rajasekhara R Mummadi; John R Petersen; Shu-Yuan Xiao; Ned Snyder
Journal:  World J Gastroenterol       Date:  2010-12-07       Impact factor: 5.742

4.  Evaluating the antifibrotic potency of galunisertib in a human ex vivo model of liver fibrosis.

Authors:  Theerut Luangmonkong; Su Suriguga; Emilia Bigaeva; Miriam Boersema; Dorenda Oosterhuis; Koert P de Jong; Detlef Schuppan; Henricus A M Mutsaers; Peter Olinga
Journal:  Br J Pharmacol       Date:  2017-08-11       Impact factor: 8.739

5.  Transplantation of fetal liver epithelial progenitor cells ameliorates experimental liver fibrosis in mice.

Authors:  Jin-Fang Zheng; Li-Jian Liang; Chang-Xiong Wu; Jin-Song Chen; Zhen-Sheng Zhang
Journal:  World J Gastroenterol       Date:  2006-12-07       Impact factor: 5.742

6.  Alcoholic liver disease patients treated with S-adenosyl-L-methionine: an in-depth look at liver morphologic data comparing pre and post treatment liver biopsies.

Authors:  Mary D Le; Elena Enbom; Peter K Traum; Valentina Medici; Charles H Halsted; Samuel W French
Journal:  Exp Mol Pathol       Date:  2013-07-23       Impact factor: 3.362

7.  Evaluation of the aspartate aminotransferase/platelet ratio index and enhanced liver fibrosis tests to detect significant fibrosis due to chronic hepatitis C.

Authors:  John R Petersen; Heather L Stevenson; Krishna S Kasturi; Ashutosh Naniwadekar; Julie Parkes; Richard Cross; William M Rosenberg; Shu-Yuan Xiao; Ned Snyder
Journal:  J Clin Gastroenterol       Date:  2014-04       Impact factor: 3.062

8.  Development of an in vitro model to test antifibrotic drugs on primary human liver myofibroblasts.

Authors:  Lynda Aoudjehane; Pierre-Yves Boelle; Grégoire Bisch; Rolland Delelo; François Paye; Olivier Scatton; Chantal Housset; Jérôme Becquart; Yvon Calmus; Filomena Conti
Journal:  Lab Invest       Date:  2016-03-07       Impact factor: 5.662

9.  Lycopene prevents development of steatohepatitis in experimental nonalcoholic steatohepatitis model induced by high-fat diet.

Authors:  Ibrahim Halil Bahcecioglu; Nalan Kuzu; Kerem Metin; Ibrahim Hanifi Ozercan; Bilal Ustündag; Kazim Sahin; Omer Kucuk
Journal:  Vet Med Int       Date:  2010-10-03

10.  HCV induces oxidative and ER stress, and sensitizes infected cells to apoptosis in SCID/Alb-uPA mice.

Authors:  Michael A Joyce; Kathie-Anne Walters; Sue-Ellen Lamb; Mathew M Yeh; Lin-Fu Zhu; Norman Kneteman; Jason S Doyle; Michael G Katze; D Lorne Tyrrell
Journal:  PLoS Pathog       Date:  2009-02-06       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.